{"id":"losartan-simvastatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Muscle pain or myalgia"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Cough"}]},"_chembl":{"chemblId":"CHEMBL1201391","moleculeType":"Small molecule","molecularWeight":"436.59"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Losartan blocks angiotensin II type 1 receptors, causing vasodilation and reducing blood pressure and aldosterone secretion. Simvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, reducing LDL cholesterol and triglycerides. Together, they provide complementary cardiovascular risk reduction in patients with both hypertension and hyperlipidemia.","oneSentence":"This combination reduces blood pressure via angiotensin II receptor blockade and lowers cholesterol via HMG-CoA reductase inhibition, addressing both hypertension and dyslipidemia simultaneously.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:53:04.270Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension with concurrent hyperlipidemia"},{"name":"Cardiovascular risk reduction in patients requiring both antihypertensive and lipid-lowering therapy"}]},"trialDetails":[{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT02188121","phase":"PHASE4","title":"Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients","status":"COMPLETED","sponsor":"Mclean Hospital","startDate":"2015-02","conditions":"Serious Mental Illness, Schizophrenia, Schizoaffective Disorder","enrollment":227},{"nctId":"NCT02246257","phase":"NA","title":"Early Rheumatoid Arthritis COR Intervention","status":"UNKNOWN","sponsor":"MD, PhD, Annemarie Lyng Svensson","startDate":"2014-09","conditions":"Rheumatoid Arthritis, Cardiovascular Diseases","enrollment":300},{"nctId":"NCT00231803","phase":"NA","title":"The Canadian Prevention of Renal and Cardiovascular Endpoints Trial","status":"COMPLETED","sponsor":"Brendan Barrett","startDate":"2005-04","conditions":"Chronic Kidney Disease","enrollment":474},{"nctId":"NCT00720577","phase":"EARLY_PHASE1","title":"Study to Evaluate the Effect of Simvastatin, Losartan and Pioglitazone on Patients With Peripheral Arterial Disease.","status":"COMPLETED","sponsor":"Medtronic Endovascular","startDate":"2005-12","conditions":"Peripheral Arterial Disease","enrollment":164},{"nctId":"NCT04343001","phase":"PHASE3","title":"Coronavirus Response - Active Support for Hospitalised Covid-19 Patients","status":"WITHDRAWN","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2020-10","conditions":"Covid-19","enrollment":""},{"nctId":"NCT04061824","phase":"PHASE4","title":"Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-05-24","conditions":"Hypertension, Dyslipidemias","enrollment":150},{"nctId":"NCT00669435","phase":"PHASE4","title":"Losartan and Simvastatin in Hypertensive Obeses With Liver Steatosis","status":"UNKNOWN","sponsor":"University of Pavia","startDate":"2008-04","conditions":"Hypertension","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":93,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Losartan + Simvastatin","genericName":"Losartan + Simvastatin","companyName":"University of Pavia","companyId":"university-of-pavia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination reduces blood pressure via angiotensin II receptor blockade and lowers cholesterol via HMG-CoA reductase inhibition, addressing both hypertension and dyslipidemia simultaneously. Used for Hypertension with concurrent hyperlipidemia, Cardiovascular risk reduction in patients requiring both antihypertensive and lipid-lowering therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}